Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clopidogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 known ✓ | Q9H244 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clopidogrel SCHEMBL30388817 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL19148648 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL14009483 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031319 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031641 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL29793709 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL5567933 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL4769 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1130036 | 0.99 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1402209 | 0.99 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109867684-A | A kind of preparation method of II type bisulfate clopidogrel | 武汉武药制药有限公司 | 2019-06-11 | — | — | CN | claimed |
| CN-109288805-B | A kind of compound aspirin bisulfate clopidogrel clad sheet and preparation method | 北京汇诚瑞祥医药技术有限公司 | 2019-05-31 | — | — | CN | claimed |
| CN-109574984-A | Novel method for synthesizing clopidogrel hydrogen sulfate and intermediate thereof | 南方科技大学 | 2019-04-05 | — | — | CN | claimed |
| CN-105748419-B | A kind of pharmaceutical composition and preparation method thereof containing spherical bisulfate clopidogrel I crystal | 深圳信立泰药业股份有限公司 | 2018-09-14 | — | — | CN | claimed |
| CN-104095861-B | Controlled release preparation of sulfated compound clopidogrel hydrogen and aspirin and preparation method thereof | 乐普药业股份有限公司 | 2017-10-03 | — | — | CN | claimed |
| CN-107157946-A | Clopidogrel hydrogen sulfate tablet and preparation method thereof | 佛山市瑞兴医药有限公司 | 2017-09-15 | — | — | CN | claimed |
| CN-104610274-B | Type I clopidogrel hydrogen sulfate salt preparation method | 亚宝药业集团股份有限公司 | 2017-04-19 | — | — | CN | claimed |
| CN-104523627-B | Clopidogrel hydrogen sulfate tablet medicine composition and preparation method thereof | 成都苑东生物制药股份有限公司 | 2017-04-12 | — | — | CN | claimed |
| CN-104095861-A | Compound hydrogen sulfate clopidogrel and aspirin controlled release preparation and preparation method thereof | LEPU PHARMACEUTICALS CO LTD | 2014-10-15 | — | — | CN | claimed |
| CN-101926756-A | Solid preparation of clopidogrel or pharmaceutically acceptable salt thereof | BEIJING SECOND PHARMACEUTICAL CO LTD | 2010-12-29 | — | — | CN | claimed |
| WO-2004098593-A1 | AMORPHOUS CLOPIDOGREL HYDROGEN SULFATE COMPOSITION | HETERO DRUGS LIMITED (IN) | 2004-11-18 | — | — | WO | claimed |
| CN-115326942-B | Analysis method for measuring thiophene tosylate | 苏州正济医药研究有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-115887403-A | Preparation method of clopidogrel tablet | 国药集团致君（深圳）制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-114272382-A | Application and pharmaceutical composition of Galectin-3 inhibitor | 上海中医药大学 | 2022-04-05 | — | — | CN | disclosed |
| CN-112587495-A | Aspirin and clopidogrel hydrogen sulfate compound preparation and preparation method thereof | 乐普药业股份有限公司 | 2021-04-02 | — | — | CN | disclosed |
| WO-2005097804-A1 | CRYSTALLINE CLOPIDOGREL NAPHTHALENESULFONATE OR HYDRATE THEREOF, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HANMI PHARM. CO., LTD. (KR) | 2005-10-20 | — | — | WO | disclosed |
| US-20050228012-A1 | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same | HANMI PHARM. CO., LTD. | 2005-10-13 | — | — | US | disclosed |
| WO-2005016931-A2 | CRYSTALLISATION OF SOLID FORMS OF CLOPIDOGREL ADDITION SALTS | KRKA, TORVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004098593-A1 | AMORPHOUS CLOPIDOGREL HYDROGEN SULFATE COMPOSITION | HETERO DRUGS LIMITED (IN) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004052966-A1 | A NOVEL POLYMORPH OF CLOPIDOGREL HYDROGEN SULFATE | HETERO DRUGS LIMITED (IN) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228012-A1 | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same | P2RY6, NUDT1, AGPS | P2RY12 11/4885ABCB11 244/4885OPRM1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.